Dave Fornell is the editor of DAIC magazine at TCT.
Dave Fornell, DAIC Editor at TCT
Blog | Dave Fornell, DAIC Editor at TCT | Cath Lab| October 16, 2018

The Innovation Cycle for New Cardiovascular Technology

The cardiovascular innovation cycle presented by TCT Course Director Martin Leon, M.D. at TCT 2018. #TCT2018 #TCT #TCT18

The cardiovascular innovation cycle, presented by TCT Course Director Martin Leon, M.D., at TCT 2018.

There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on clinical trial data as one of the key determining factors of whether a new device becomes standard of care or dies on the vine. Here is a great summary of this cycle with cardiovascular devices.

Over the past decade of covering the Transcatheter Cardiovascular Therapeutics (TCT) meetings, I have seen an interesting slide on the innovation cycle for interventional cardiology device technologies presented numerous times by Course Director Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy and professor of medicine, NewYork-Presbyterian, Columbia University Medical Center. The slide is always the same since he first presented it at TCT in 1993, but it holds universally true today in 2018. 

Leon said the cycle starts with the introduction of a new technology that garners unbridled enthusiasm because of the promise the technology holds to solve problems with the current standard of care. The early data seems great and when it enters the market, there is rapid adoption as everyone wants to try to use it. However, there are inevitably some complications that are discovered once the technology is used on a large scale, either due to implant, operator skill or previously unknown complications. When data on the complications are presented, there is a steep drop-off in the use of the technology. 

At this point in the cycle, Leon said it is important to refine the technology to overcome the issues presented by the first-generation device. Once that is achieved and clinical data confirms the issues are resolved, there is a second wave of adoption for the technology, as cardiologists are cautiously optimistic about using the improved technology. He said that crash where the enthusiasm dissolves because of cold, hard data is when the real science of refining the technology into something better can take place. 

Certainly this cycle mirrored the case with drug-eluting stents and the discovery of polymer-related late-stent thrombosis. The same is true with renal denervation and bioresorbable stents.

At TCT 2018, Leon used this slide in sessions to describe where interventional cardiology is at today with bioresorbable stent technology — at the bottom of the abyss. However, he said there are new bioresorbable technologies still being developed that already hold promise to resolve the issues inherent with the first-generation Absorb stent. This includes new bioresorbable scaffolds (BRS) that use different polymers to possibly avoid late thrombosis, and devices with the same strut thickness of today's metallic stents to make the devices easier to deliver and allow use in smaller vessels. 

Two years ago, all TCT sessions on bioresorbable technologies were packed and it seemed as if metallic stents had no long-term future. What a difference a year makes from TCT 2017, when the poor ABSORB III Trial data was presented and Abbott pulled the Absorb off the market. At TCT 2018, bioresorbable technology definitely took a back seat to metallic stent presentations, where the industry has definitely refocused its interest. 

"I want to be a wild enthusiast, not a doubting skeptic," Leon said about BRS technology. "The Absorb was not easy to use and there was a safety concern. The safety signal is really what distracted people's attention with bioresorbable stents. We are not going to have an avalanche of new bioresorbable stents, but there will be a few second-generation stents that have overcome the limitations of the first-generation stent."

However, the new clinical evidence will have to be persuasive enough with these new BRS devices to convince him and the rest of the interventional cardiology community that the technology is truly ready for prime time.

Read the article from TCT 2018 "The Next Step in Bioresorbable Stent Technologies."

Watch an interview with Patrick Serruys, M.D., about the future of BVS technology.

Related Content

Medicare Trustees Report Hospital Insurance Trust Fund Will Deplete in Seven Years
News | Cardiovascular Business | April 22, 2019
The Medicare Hospital Insurance (HI) Trust Fund, which funds Medicare Part A, will only be able to pay full benefits...
Videos | Cardiovascular Business | April 16, 2019
A discussion with Ruth Fisher, MBA, vice president of the...
Foreign-trained doctors now make up one-third of cardiologists in the United States and help make up for the U.S. overall shortage of physicians. Pictured here is co-author of this article Mandeep R. Mehra, MBBS, MSc, FRCP, who is an example of the contribution international physicians have made in the U.S. He is medical director of the Brigham and Women’s Hospital Heart and Vascular Center.

Foreign-trained doctors now make up one-third of cardiologists in the United States and help make up for the overall shortage of physicians. Pictured here is co-author of this article Mandeep R. Mehra, MBBS, MSc, FRCP, who is an example of the contribution international physicians have made in the U.S. He is medical director of the Brigham and Women’s Hospital Heart and Vascular Center, The William Harvey Distinguished Chair in Advanced Cardiovascular Medicine, and a professor of medicine at Harvard Medical School. He is past-president of both the Heart Failure Society of America and the International Society of Heart and Lung Transplantation. 

Feature | Cardiovascular Business | April 15, 2019 | William W. Pinsky, M.D., FAAP, FACC, and Mandeep R. Mehra, MBBS, MSc , FRCP
As we strive to process today’s successive news cycles involving negative reports about immigration, it is easy for m
ACC Combines NCDR, Accreditation Into New Quality Summit
News | Cardiovascular Business | March 15, 2019
The American College of Cardiology’s first annual ACC Quality Summit, held March 13-15 in New Orleans, merges the NCDR...
Diagnostic and Interventional Cardiology Named 2019 Azbee Awards Finalist for Social Media
News | Cardiovascular Business | March 08, 2019 | Jeff Zagoudis, Associate Editor
Diagnostic and Interventional Cardiology (DAIC) was named a finalist in the Social Media Presence category for the 2019...
 FDA Commissioner Scott Gottlieb Announces Resignation
News | Cardiovascular Business | March 05, 2019 | Jeff Zagoudis, Associate Editor
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D., resigned from his position March 5 after two...
Diagnostic and Interventional Cardiology Honored as Jesse H. Neal Awards Finalist

An example of the new transesophageal echo (TEE) visualization technology called TrueVue was shown at TCT 2018 for the first time. Philips’ new photo-realistic rendering is designed to offer a surgical view of cardiac structures to aid transcatheter procedural navigation.

News | Cardiovascular Business | February 25, 2019
Diagnostic and Interventional Cardiology has been recognized as a finalist in the Jesse H. Neal Awards for the third...
GE to Postpone Healthcare IPO Following Biopharmaceutical Business Sale
News | Cardiovascular Business | February 25, 2019 | Jeff Zagoudis, Associate Editor
GE Healthcare announced Feb. 25 the sale of its biopharmaceutical business to Danaher, and GE Chairman and CEO Larry...
Medical Bills Financially Burden Almost Half of Cardiovascular Disease Patients
News | Cardiovascular Business | February 11, 2019
Over 45 percent of adult atherosclerotic cardiovascular disease (ASCVD) patients suffer financial hardship related to...
Overlay Init